Preeclampsia Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Antihypertensive Agents, Anticonvulsants, Antiplatelet Agents, Calcium Supplements, and Others), By Disease Type (Mild Preeclampsia and Severe Preeclampsia), By Treatment Phase (Antenatal Management, Intrapartum Management, and Postpartum Management), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2026-2034

The global preeclampsia therapeutics market size was valued at USD 380.0 million in 2025. The market is projected to grow from USD 414.7 million in 2026 to USD 758.1 million by 2034, exhibiting a CAGR of 7.83% during the forecast period.

Preeclampsia refers to persistent high blood pressure that develops during pregnancy or the postpartum period. It is often associated with high levels of protein in the urine, issues related to kidneys or liver, fluid in the lungs, or signs of brain trouble such as seizures and/or visual disturbances. The global therapeutics market is supported by the rising burden of hypertensive disorders during pregnancy and growing focus on reducing preventable maternal and fetal complications. Severe risks associated with uncontrolled preeclampsia are encouraging healthcare providers to strengthen antenatal screening, early risk assessment, blood-pressure management, seizure prevention, and postpartum follow-up. Treatment demand is primarily driven by the need for antihypertensive agents, magnesium sulfate, preventive low-dose aspirin, and calcium supplements for eligible patients. Pharmaceutical companies are also focusing on ready-to-use hospital formulations and novel therapies targeting vascular dysfunction, placental abnormalities, and angiogenic imbalance to improve treatment outcomes. Expanding institutional deliveries, maternal-health programs, and clinical research activities are expected to strengthen overall market growth.

• For instance, in March 2026, DiaMedica Therapeutics received Health Canada clearance to initiate a Phase 2 study of DM199 in women with early-onset preeclampsia. The study is evaluating safety, tolerability, angiogenic biomarkers, uterine-artery function, maternal and fetal complications, and gestational age at delivery. This development highlights the increasing focus of pharmaceutical companies on therapies that may address vascular and placental dysfunction rather than relying solely on conventional symptom-control medicines.

Furthermore, key players in the market, such as Fresenius Kabi AG, Pfizer Inc., Baxter International Inc., and Hikma Pharmaceuticals PLC are expanding their offerings to enhance therapeutics’ access and strengthen their market presence.

PREECLAMPSIA THERAPEUTICS MARKET TRENDS

Shift Toward Standardized Preeclampsia Treatment Protocols is a Prominent Market Trend

Standardization of preeclampsia treatment protocols is an emerging global trend as delays in confirming severe blood pressure, administering antihypertensive medication, initiating magnesium sulfate, conducting laboratory investigations, or escalating the patient to higher-level care can lead to avoidable complications. This trend supports more predictable hospital demand for medicines listed in clinical guidelines. Facilities implementing standardized bundles are more likely to maintain readily accessible inventories of magnesium sulfate, antihypertensive injections, oral nifedipine, corticosteroids, and associated administration supplies.

Standardized treatment also encourages procurement of products in consistent strengths and ready-to-use formats that align with hospital algorithms, reducing variation in preparation and administration. 

• For instance, in 2025, the Alliance for Innovation on Maternal Health published a Severe Hypertension in Pregnancy Change Package to support implementation of its patient-safety bundle. The package is structured around readiness, recognition and prevention, response, reporting and systems learning, and respectful care across maternal-health settings.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Burden of Preeclampsia to Drive Market Growth

Rising disease burden of preeclampsia is expanding the number of pregnant women requiring preventive medication, driving global preeclampsia therapeutics market growth. Consequently, a larger diagnosed patient population directly increases the use of antihypertensive agents, magnesium sulfate, corticosteroids, low-dose aspirin, calcium supplements, and other supportive therapies across antenatal, intrapartum, and postpartum settings. Healthcare providers are increasingly adopting closer prenatal monitoring and earlier preventive intervention, thereby broadening the addressable population for preeclampsia-related therapeutics. 

• For instance, in July 2026, the U.S. Centers for Disease Control and Prevention reported that the rate of gestational hypertension among mothers giving birth increased from 6.0% in 2016 to 10.4% in 2024, representing a 73% increase. The report also observed higher rates among women aged 40 years and above, women with increasing pre-pregnancy body mass index, and women with twin or higher-order multiple births. The trend indicates a significant expansion of the population potentially requiring clinical management.

MARKET RESTRAINTS

Limited Availability of Disease-Modifying Therapies and High Costs of Clinical Trials to Restrain Market Growth

Currently available products mainly help to control symptoms such as high blood pressure and prevent complications including seizures associated with the condition. These products do not eliminate placental dysfunction or prevent disease progression in every patient. The absence of a disease-modifying therapy also results in substantial dependence on mature, genericized medicines. This limits product differentiation, premium pricing, and revenue expansion, particularly in public-sector procurement markets where purchasing decisions are strongly influenced by price and essential medicine availability.

Additionally, clinical trials involve high development costs, complicated patient recruitment, and delayed progression into large controlled trials, further hampering market growth.

• For instance, in July 2025, DiaMedica Therapeutics reported interim results from an investigator-sponsored Phase 2 study of DM199, or rinvecalinase alfa. Although early blood-pressure and uterine-artery findings were encouraging, the study was an open-label, single-centre, single-arm proof-of-concept trial, and the overall program remained at the Phase 2 development stage. DiaMedica also acknowledged that no approved disease-modifying pharmacological treatment was available for preeclampsia in the U.S. and Europe, demonstrating that even promising pipeline candidates remain several development and regulatory steps away from commercialization.

MARKET OPPORTUNITIES

Development of Novel Therapies Targeting Placental Dysfunction to Create High-Value Market Growth Opportunities

A prominent growth opportunity in the global market is the development of medicines that target placental dysfunction, endothelial injury, impaired uteroplacental blood flow, and angiogenic imbalance rather than restricting to prevent seizures. Emerging candidates are targeting mechanisms such as excessive placental sFlt-1 production, endothelial dysfunction, impaired vasodilation, and reduced placental perfusion. Successful development could support biomarker-selected treatment, regulatory exclusivity, premium pricing, and higher pharmaceutical investment in a historically underfunded pregnancy-specific disease area.

• For instance, in April 2025, Comanche Biopharma announced that the European Medicines Agency granted orphan-drug designation to CBP-4888 for sFlt-1-mediated preterm preeclampsia. The investigational siRNA candidate is designed to reduce excessive placental sFlt-1 production and potentially prolong pregnancy by addressing a pathogenic mediator of the condition.

MARKET CHALLENGES

Low Treatment Accessibility in Developing and Underserved Regions Restricts Diagnosis-to-Treatment Conversion

The global market is restrained by limited access to antenatal screening, skilled obstetric care, specialist consultation, and emergency treatment across low-income, rural, conflict-affected, and geographically remote populations. Women who cannot access these services may remain undiagnosed or receive treatment only after the condition progresses to severe preeclampsia or eclampsia. Significant socioeconomic and geographic disparities continue to restrict access to supervised maternity care. Consequently, a considerable proportion of patients in underserved markets may not receive low-dose aspirin during the preventive or early disease progression stage. This lowers treatment adoption despite the substantial underlying clinical need.

• For instance, in April 2025, WHO and other UN agencies warned that reductions in international health funding were forcing countries to close healthcare facilities, reduce their health workforce, and disrupt supply chains for medicines used to treat preeclampsia and other major maternal complications. Such service reductions are expected to restrict further the conversion of eligible pregnant women into diagnosed and treated patients.

Segmentation Analysis

By Drug Class

Broad Use During Mild And Severe Preeclampsia to Sustain Antihypertensive Agents’ Leading Share

Based on drug class, the market is segmented into antihypertensive agents, anticonvulsants, antiplatelet agents, calcium supplements, and others.

The antihypertensive agents segment dominated as blood-pressure control represents a central component of the treatment across mild and severe preeclampsia during antenatal, intrapartum, and postpartum management. Oral products such as labetalol, nifedipine, and methyldopa support continuing blood pressure management. This broad clinical application creates a substantially larger addressable population than anticonvulsants, which are mainly used for severe preeclampsia and eclampsia. Antiplatelet agents and calcium supplements are primarily preventive and restricted to eligible high-risk groups, further supporting the higher share of antihypertensive agents.

• For instance, in March 2026, Amneal Pharmaceuticals launched Labetalol Hydrochloride Injection, USP, in a 20 mg/4 mL prefilled syringe presentation. The ready-to-administer, preservative-free product expands hospital access to a rapid-acting antihypertensive formulation and supports efficient treatment of severe blood-pressure elevations.

The calcium supplements segment is projected to grow at a CAGR of 9.07% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Disease Type

Larger Diagnosed Patient Pool and Longer Management Period to Support Mild Preeclampsia Segment Dominance

Based on disease type, the market is categorized into mild preeclampsia and severe preeclampsia.

The mild preeclampsia segment dominated the market as a larger proportion of patients are identified before developing seizures, severe hypertension, organ dysfunction, or other severe clinical features. Expanding antenatal blood-pressure screening and home monitoring are enabling healthcare providers to recognize the condition earlier, which increases the number of women receiving regular monitoring and pharmacological management. These patients may remain under clinical management until approximately 37 weeks of pregnancy, creating a longer treatment window than severe cases, where urgent delivery may be required at or after 34 weeks or earlier if complications develop. Consequently, the larger patient pool and longer use of oral antihypertensive and supportive therapies increase the segment’s overall share.

• For instance, in July 2025, the Indiana Hospital Association collaborated with the Preeclampsia Foundation to distribute 9,000 self-measured blood-pressure kits through 169 birthing hospitals and other maternal-health providers. The program enables women to monitor blood pressure between prenatal visits, helping providers identify and treat hypertensive disorders before they progress to severe preeclampsia.

The severe preeclampsia segment is expected to grow at a CAGR of 7.30% over the forecast period.

By Treatment Phase

Longer Duration Preventive and Therapeutic Window Makes Antenatal Management the Most Favored Treatment Phase

Based on treatment phase, the market is segmented into antenatal management, intrapartum management, and postpartum management.

In 2025, the antenatal management segment dominated the market as majority preventive and continuing treatment is initiated during pregnancy and maintained until delivery. High-risk women patients may receive low-dose aspirin after the first trimester. At the same time, diagnosed patients may require repeated antihypertensive treatment, maternal and fetal monitoring, and corticosteroids when preterm delivery is anticipated. As antenatal management can extend for several weeks or months, it generates higher cumulative medicine consumption than intrapartum management.

• For instance, in December 2025, King’s College Hospital reported results from the PREVENT-PE trial, which enrolled more than 8,000 women and evaluated preeclampsia-risk screening at 36 weeks followed by planned early-term delivery according to individual risk. The strategy reduced the incidence of term preeclampsia by 30%, highlighting the increasing importance of structured risk assessment and intervention during the antenatal phase.

The postpartum management is expected to grow at a CAGR of 8.08% over the forecast period.

By Route of Administration

Oral is the Mostly Used Route of Administration Owing to Extended Outpatient Use and Convenient Administration

Based on route of administration, the market is segmented into oral and parenteral.

In 2025, the oral segment dominated the market due to the widespread and repeated use of oral antihypertensive agents, low-dose aspirin, and calcium supplements. Oral therapies can be administered at home and in outpatient settings, require limited clinical infrastructure, and are suitable for treatment lasting several weeks or months. Nifedipine, labetalol, and methyldopa are established options for managing pregnancy-related hypertension, while low-dose aspirin is recommended after 12 weeks of gestation for eligible high-risk women. These factors contribute to the dominance of the segment.

• For instance, in January 2025, the Preeclampsia Foundation and Patients & Purpose launched the GAP—SPIRIN campaign to encourage appropriate low-dose aspirin use among high-risk Black pregnant women. The initiative initially provided education and prescribing resources to 100 community obstetric practices across five high-risk New York City ZIP codes, supporting wider adoption of oral preventive therapy during pregnancy.

The parenteral segment is projected to grow at a CAGR of 6.06% over the forecast period.

By Distribution Channel

Hospital Pharmacies Segment Dominated Owing to Concentration of Emergency Obstetric Treatment in Hospitals

Based on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, online pharmacies, and others.

The hospital pharmacies segment captured the largest share in the market as preeclampsia and eclampsia require immediate access to prescription medicines, continuous maternal–fetal monitoring, and emergency-delivery capabilities. Hospital pharmacies maintain inventories offering products required for rapid clinical intervention. Magnesium sulfate administration and intravenous antihypertensive treatment also require trained professionals and close monitoring, which concentrates their procurement and consumption within hospitals and maternity centers. These factors contribute to the growth of the global market.

• For instance, in April 2026, SteriMax announced the Canadian launch of Magnesium Sulfate Injection, USP, in 10 mL and 50 mL vial formats. The hospital-focused presentations include unit-level two-dimensional barcodes intended to support medication identification and healthcare-provider workflows, strengthening institutional availability of an essential medicine used in severe preeclampsia and eclampsia management.

The online pharmacies segment is projected to grow at a CAGR of 15.97% over the forecast period.

Preeclampsia Therapeutics Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the second largest share in 2024 at USD 100.4 million and maintained its position in 2025 at USD 108.7 million. The market is growing due to the rising incidence of hypertensive disorders during pregnancy, which is expanding the population requiring antihypertensive treatment, seizure prevention, and postpartum management. Advanced hospital infrastructure, home blood-pressure monitoring, and early risk assessment are further increasing diagnosis and treatment adoption.

U.S. Preeclampsia Therapeutics Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated at around USD 112.5 million in 2026, accounting for roughly 27.13% of the global market.

Europe

Europe is projected to grow at 7.28% over the coming years, third-highest among all regions, and reach a valuation of USD 70.9 million by 2026. The market is expanding owing to standardized antenatal-care pathways, strong specialist maternity services, and increasing use of evidence-based preventive and therapeutic protocols. Regional investment in maternal-health research, placental biomarkers, and innovative preeclampsia treatments is also supporting regional market growth.

U.K. Preeclampsia Therapeutics Market

The U.K. market is estimated at USD 10.7 million in 2026, accounting for roughly 2.59% of the global market.

Germany Preeclampsia Therapeutics Market

The market in Germany is projected to reach approximately USD 9.6 million in 2026, equivalent to around 2.31% of the global market.

Asia Pacific

Asia Pacific is estimated to reach USD 149.8 million in 2026 and secure the leading preeclampsia therapeutics market share. The market is growing due to the region’s large pregnant population and expanding antenatal screening, institutional-delivery, and high-risk pregnancy-management programs. Strengthening emergency obstetric-care networks and the maternal-health workforce is improving access to antihypertensives, magnesium sulfate, aspirin, calcium supplements, and other essential therapies.

Japan Preeclampsia Therapeutics Market

The Japanese market in 2026 is estimated at around USD 8.9 million, accounting for approximately 2.14% of the global market.

China Preeclampsia Therapeutics Market

China's market is projected to be among the largest worldwide, with 2026 revenues estimated at around USD 47.9 million, accounting for approximately 11.55% of global sales.

India Preeclampsia Therapeutics Market

The Indian market in 2026 is estimated at around USD 39.2 million, accounting for roughly 9.45% of global revenue.

Latin America and Middle East & Africa

The Latin America region is expected to witness moderate growth in this market during the forecast period. The market in Latin America is estimated to reach a valuation of USD 33.5 million. The market is expanding as governments and healthcare organizations strengthen maternal-care services to address the region’s substantial burden of preventable pregnancy-related complications. Improved prenatal screening, referral pathways, healthcare-worker training, and access to emergency obstetric treatment are increasing diagnosis-to-treatment conversion. In the Middle East & Africa, the GCC is set to reach USD 14.3 million in 2026.

South Africa Preeclampsia Therapeutics Market

The South African market is projected to reach approximately USD 4.9 million by 2026, accounting for roughly 1.17% of global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Product Innovation and Omnichannel Expansion by Key Companies to Intensify Market Competition

The global preeclampsia therapeutics market is moderately fragmented, with competition primarily led by companies such as Fresenius Kabi AG and Pfizer Inc., and Baxter International Inc. maintaining strong positions through magnesium sulfate injections offered in vials, syringes, and flexible containers. At the same time, Hikma Pharmaceuticals PLC strengthens its presence through labetalol injections supplied in prefilled syringes and ready-to-use infusion bags. These product formats reduce hospital preparation requirements and support rapid medicine administration during severe hypertension, preeclampsia, and eclampsia emergencies.  

Other participants in the market include regional generic-drug companies, injectable manufacturers, government suppliers, and maternal-health medicine distributors. They are expected to compete through tender pricing, country-level product registrations, consistent medicine availability, local manufacturing, and distribution relationships with hospitals and public-health systems. Established players are likely to retain stronger near-term positions due to their sterile-manufacturing capacity, hospital customer networks, regulatory approvals, and ability to supply multiple dosage forms. However, regional manufacturers may gain share by offering cost-effective oral antihypertensive agents, magnesium sulfate, aspirin, calcium products, and other guideline-used medicines in underserved markets.

LIST OF KEY PREECLAMPSIA THERAPEUTICS COMPANIES PROFILED

• Fresenius Kabi AG (Germany)
• Pfizer Inc. (U.S)
• Baxter International Inc. (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Braun SE (Germany)
• Bayer AG (Germany)
• Aurobindo Pharma Limited (India)
• Zydus Group (India)

KEY INDUSTRY DEVELOPMENTS

• July 2026: The Preeclampsia Foundation launched a patient-informed toolkit to support the national Aspirin Study and increase awareness of low-dose aspirin among eligible high-risk pregnant women. The initiative is directly relevant to the preeclampsia therapeutics market as it boosts the identification, recommendation, and antenatal use of antiplatelet agents for preeclampsia prevention.
• June 2026: DiaMedica received written FDA feedback on the nonclinical development requirements for DM199, or rinvecalinase alfa, to support a planned U.S. preeclampsia IND. The development holds significance as DM199 could potentially become a preeclampsia-specific disease-modifying therapy.
• February 2026: Fresenius Kabi Canada removed allocation restrictions on its magnesium sulfate injection 500 mg/mL, 50 mL presentation. This improves the availability of a core anticonvulsant therapy used parenterally through hospital pharmacies for seizure prophylaxis in severe preeclampsia and for eclampsia management.
• January 2026: Baxter updated its ready-to-use magnesium sulfate VIAFLO portfolio, including premixed hospital presentations. These formulations are relevant to key segments such as severe preeclampsia as ready-to-use bags can simplify preparation and support rapid administration in obstetric emergencies.
• July 2025: DiaMedica raised USD 30 million to accelerate development of DM199 for preeclampsia and related pregnancy complications. The financing supports clinical and regulatory advancement of a potential disease-modifying preeclampsia therapy and strengthens the future drugs pipeline.

REPORT COVERAGE

The global preeclampsia therapeutics report provides market size and forecast for all the segments included in the report. The market outlook also details the key market dynamics and trends expected to influence market growth during the forecast period. It offers information on the rising prevalence of hypertensive disorders during pregnancy, increasing antenatal screening, expansion of institutional deliveries, growing use of antihypertensive agents and preventive therapies, and improving access to emergency obstetric care across key regions and countries. It also covers major industry developments, clinical-trial progress, product launches, regulatory approvals, strategic partnerships, collaborations, manufacturing expansions, and other initiatives undertaken by key companies. In addition, the report provides a comprehensive global preeclampsia therapeutics market analysis. It includes regional analysis, market dynamics, segmental insights, company market-share analysis, product portfolios, strategic initiatives, SWOT analysis, and detailed profiles of the key market participants.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation